Penfluridol, a Unique Psychiatric Medicine for the Treatment of Chronic Schizophrenia
Download in electronic PDF format for $75
Abstract: Schizophrenia is a serious, disabling, enduring, and relapsing mental illness which causes problems with the ability to think, feel, and perceive things clearly. One cause of relapse and readmission to a hospital is poor compliance with antipsychotic medication, often due to its adverse effects. Schizophrenia may also affect a person’s insight, interfering with their ability to appreciate the benefit of taking medication long term. The relapse rate is significantly higher in those who have discontinued antipsychotic medication. Penfluridol is an unusual, potent, long-acting, first-generation, oral antipsychotic agent indicated for the treatment of chronic schizophrenia, acute psychosis, and Tourette syndrome. It may be considered a depot medication, as it is administered once a week. Despite this positive analysis, and the unique added value of this medication to psychotic, non-compliant patients, Janssen-Cilag, the sole manufacturer of penfluridol worldwide, decided to stop production in 2009. This decision forced many psychotic patients worldwide to abandon the once-a-week convenient treatment and to replace it with a daily, oral treatment or a depot injection. Because penfluridol is no longer commercially available, it has created an opportunity for compounding pharmacists worldwide to accept this challenge and offer this medication to psychiatrists because of its clinical therapeutics. For the past 5 years, penfluridol has been available to compounding pharmacists in Israel and has received favorable feedback from physicians and patients.
Related Keywords:
Eyal Zur, BSc Pharm, RPh, MBA, penfluridol, formulations, diphenylbutylpiperidine, chronic schizophrenia, antipsychotic agents, acute psychosis, Tourette syndrome, psychiatric disorders, postsynaptic dopamine receptor, mesolimbic dopaminergic system, neuroleptic adverse effects, drug interactions, herbal supplements, depot administration
Related Articles from IJPC |
Title/Author
(Click for Abstract / Details / Purchase) |
Issue/Page
View/Buy |
Penfluridol, a Unique Psychiatric Medicine for the Treatment of Chronic Schizophrenia
Zur Eyal
|
Mar/Apr 2019
Pg. 113-119
|
Drug Therapy for Acute and Chronic Pain in the Cat
Lascelles B Duncan
|
Sep/Oct 2002
Pg. 338-343
|
Wetting and/or Solubilizing Agents, Featured Excipient:
Allen Loyd V Jr
|
Jul/Aug 2001
Pg. 310-312
|
Sensitization Therapy for Warts
Kuntz Rachael
|
Jul/Aug 2003
Pg. 266-270
|
PostScription: Treatment of Chronic Pain with Methadone or Levorphanol
McNulty Jack P
|
Mar/Apr 2006
Pg. 159-160
|
A Compendium of Compounding Agents and Formulations, Part 6: Additional Preparations for Refractory Dermal-wound Healing
Riepl Mike
|
Nov/Dec 2022
Pg. 480-488
|
Compounding for the Treatment of COVID-19 and Long COVID, Part 4: The Legacy of Chronic COVID
Riepl Mike, Kaiser Joe
|
Jul/Aug 2023
Pg. 284-293
|
Levorphanol, Methadone, and the Management of Intractable Chronic Pain: An Interview with Kerry Schmidt, BA, MBA; Jack P. McNulty, MD, FACP; and George B. Muller, RPh
Vail Jane
|
Jan/Feb 2006
Pg. 9-11
|
Aripiprazole 1 mg/mL in Oral-Plus:Ora-Sweet (1:1) Oral Suspension
Allen Loyd V Jr
|
Jul/Aug 2019
Pg. 314
|
Treatment of Dermatologic Adverse Events Induced by Oncological Treatments Using Compounded Medications
Zur Eyal
|
Nov/Dec 2018
Pg. 446-454
|
Using Compounded Medications for the Topical Treatment of Complex Regional Pain Syndrome Type I Following Trauma: A Case Report
Zur Eyal
|
Jan/Feb 2014
Pg. 14-19
|
Haloperidol 0.5-mg/mL in SyrSpend SF pH4
Allen Loyd V Jr
|
Sep/Oct 2021
Pg. 417
|
Haloperidol 5-mg/mL Injection
Allen Loyd V Jr
|
Nov/Dec 2017
Pg. 493
|
Stability of Compounded Diltiazem Hydrochloride in Cream, Ointment, and Gel Formulations for Topical Use
Teimouri Arezou, Yeung Pollen, Agu Remigius U
|
Nov/Dec 2020
Pg. 482-490
|
Basics of Compounding for Raynaud's Disease
Glasnapp Andrew
|
Jul/Aug 2003
Pg. 288-291
|
Equine Cushing’s Syndrome
Vail Jane
|
Jan/Feb 2003
Pg. 27-29
|
Compounded Pimobendan for Canine Chronic Degenerative Mitral Valve Disease and Pulmonary Hypertension
Helms Scott R, Fox Samantha, Mixon William, Vail Jane
|
Jan/Feb 2012
Pg. 34-41
|
Compounding for Patients with Polycystic Ovarian Syndrome (Stein-Leventhal Syndrome)
Riepl Mike
|
May/Jun 2019
Pg. 192-199
|
Topical Treatment of Primary Focal Hyperhidrosis, Part 2
Zur Eyal
|
Mar/Apr 2019
Pg. 94-104
|
Low-Dose Naltrexone: A New Therapy Option for Complex Regional Pain Syndrome Type I Patients
Sturn Kayla M, Collin Michael
|
May/Jun 2016
Pg. 197-201
|
Return to Top |